Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phenotype and Genotype of Advanced Premalignant Head and Neck Lesions After Chemopreventive Therapy

Open access
Mao, L., Papadimitrakopoulou, V., Shin, D. M., Fan, Y., Zhou, X., Lee, J. S., Hong, W. K., El-Naggar, A. K., Shin, H. C., Clayman, G., Lee, J. J., Hittelman, W. N., Lippman, S. M. · 1998 · JNCI Journal of the National Cancer Institute

Abstract

BACKGROUND: The goal of chemoprevention is to reduce the risk of cancer development by reversing or blocking the tumorigenic process through the use of pharmacologic or natural agents. To determine the potential role of genetic alterations in assessing cancer risk and in evaluating the efficacy of chemopreventive agents, we studied 22 patients with advanced premalignant lesions of the head and neck who were part of a prospective cancer prevention trial that is investigating a regimen of 13-cis-retinoic acid, interferon alfa, and alpha-tocopherol administered for 12 months or until disease progression. METHODS: We used polymerase chain reaction analysis of microsatellite DNA sequences in cells from precancerous lesions to determine the frequencies of genetic alterations--namely, loss of heterozygosity (LOH) and microsatellite instability--at chromosomal loci that are commonly deleted in head and neck cancer. RESULTS: Prior to treatment, 17 (81%) of 21, eight (44%) of 18, and eight (42%) of 19 patients who were informative (i.e., heterozygous) at chromosomes 9p21, 3p14, and 17p13, respectively, exhibited LOH in at least one of their lesion biopsy specimens. Among nine patients who exhibited LOH at chromosome 9p21 in pretreatment biopsy specimens and who had completed at least 5 months of therapy, the genetic loss persisted in eight--including three of the four patients who exhibited complete histologic responses (i.e., no evidence of dysplasia in their biopsy specimens). IMPLICATION: Our data suggest that clinical and histologic assessments of the response to chemopreventive agents may be insufficient to determine their efficacy and that critical genetic alterations could be used as independent biomarkers to augment the ability to evaluate the efficacy of such agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/90.20.1545

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 168

Metadata

Authors
Mao, L., Papadimitrakopoulou, V., Shin, D. M., Fan, Y., Zhou, X., Lee, J. S., Hong, W. K., El-Naggar, A. K., Shin, H. C., Clayman, G., Lee, J. J., Hittelman, W. N., & Lippman, S. M.
Venue
JNCI Journal of the National Cancer Institute
Published
1998-10-21
Volume
90
Issue
20
Pages
1545-1551
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2106975992
Cited by
168
References
3
FWCI
16.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phenotype and Genotype of Advanced Premalignant Head and Neck Lesions After Chemopreventive Therapy. https://app.cochat.ai/papers/10.1093/jnci/90.20.1545
The paper
Mao, L., Papadimitrakopoulou, V., Shin, D. M., Fan, Y., Zhou, X., Lee, J. S., Hong, W. K., El-Naggar, A. K., Shin, H. C., Clayman, G., Lee, J. J., Hittelman, W. N., & Lippman, S. M. (1998). Phenotype and Genotype of Advanced Premalignant Head and Neck Lesions After Chemopreventive Therapy. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/90.20.1545

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.